The anti-malaria drug that President Trump touted as a possible treatment for coronavirus, hydroxychloroquine, successfully lowered the death rate among hospitalized COVID-19 patients in the most recent study of the drug.
The large-scale analysis, conducted by Henry Ford Health System, was published Thursday in the peer-reviewed International Journal of Infectious Diseases.
The study examined 2,541 patients who had been hospitalized in six hospitals between March 10 and May 2, 2020.
More than twenty-six percent (26.4%) of patients who did not receive hydroxychloroquine died.
But among those who received hydroxychloroquine, fewer than half that number — 13% — died.